ADMA BIOLOGICS, INC.ADMAEarnings & Financial Report
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Revenue
$117.5M
Gross Profit
$63.3M
Operating Profit
$38.3M
Net Profit
$111.9M
Gross Margin
53.9%
Operating Margin
32.6%
Net Margin
95.2%
YoY Growth
59.1%
EPS
$0.45
ADMA BIOLOGICS, INC. Q4 FY2024 Financial Summary
ADMA BIOLOGICS, INC. reported revenue of $117.5M (up 59.1% YoY) for Q4 FY2024, with a net profit of $111.9M (up 734.2% YoY) (95.2% margin). Cost of goods sold was $54.2M, operating expenses totaled $25.0M.
Key Financial Metrics
| Total Revenue | $117.5M |
|---|---|
| Net Profit | $111.9M |
| Gross Margin | 53.9% |
| Operating Margin | 32.6% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
ADMA BIOLOGICS, INC. Q4 FY2024 revenue of $117.5M breaks down across 2 segments, led by ADMA Bio Manufacturing Segment at $116.4M (99.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| ADMA Bio Manufacturing Segment | $116.4M | 99.0% |
| Plasma Collection Centers Segment | $797.0K | 0.7% |
ADMA BIOLOGICS, INC. Revenue by Segment — Quarterly Trend
ADMA BIOLOGICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as ADMA Bio Manufacturing Segment and Plasma Collection Centers Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| ADMA Bio Manufacturing Segment | $123.1M | $134.2M | $121.9M | $113.7M |
| Plasma Collection Centers Segment | — | — | — | $1.1M |
ADMA BIOLOGICS, INC. Annual Revenue by Year
ADMA BIOLOGICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $510.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $510.2M |
| 2024 | $426.5M |
| 2023 | $258.2M |
| 2022 | $154.1M |
ADMA BIOLOGICS, INC. Quarterly Revenue & Net Profit History
ADMA BIOLOGICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $139.2M | +18.4% | $49.4M | 35.5% |
| Q3 FY2025 | $134.2M | +12.0% | $36.4M | 27.1% |
| Q2 FY2025 | $122.0M | +13.8% | $34.2M | 28.1% |
| Q1 FY2025 | $114.8M | +40.2% | $26.9M | 23.4% |
| Q4 FY2024 | $117.5M | +59.1% | $111.9M | 95.2% |
| Q3 FY2024 | $119.8M | +78.1% | $35.9M | 30.0% |
| Q2 FY2024 | $107.2M | +78.3% | $32.1M | 29.9% |
| Q1 FY2024 | $81.9M | +43.9% | $17.8M | 21.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.9M | $107.2M | $119.8M | $117.5M | $114.8M | $122.0M | $134.2M | $139.2M |
| YoY Growth | 43.9% | 78.3% | 78.1% | 59.1% | 40.2% | 13.8% | 12.0% | 18.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $350.9M | $376.4M | $390.6M | $488.7M | $510.6M | $558.4M | $568.7M | $624.2M |
| Liabilities | $197.2M | $188.1M | $158.7M | $139.7M | $137.2M | $160.1M | $137.5M | $146.9M |
| Equity | $153.7M | $188.3M | $231.9M | $349.0M | $373.4M | $398.3M | $431.2M | $477.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.2M | $45.6M | $25.0M | $50.2M | $-19.7M | $21.1M | $13.3M | $35.6M |